Trial Profile
Expanded Access to Rovalpituzumab Tesirine
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 11 Sep 2019
Price :
$35
*
At a glance
- Drugs Rovalpituzumab tesirine (Primary)
- Indications Small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
- 09 Sep 2019 Status changed from recruiting to completed.
- 23 Apr 2018 New trial record